BioCentury
ARTICLE | Clinical News

Almirall's nail solution of terbinafine meets in Phase III for onychomycosis

January 4, 2019 5:10 AM UTC

Almirall S.A. (Madrid:ALM) said P-3058 met the primary endpoint vs. vehicle of improving complete cure rate in a Phase III trial to treat mild-to-moderate onychomycosis. Complete cure was defined as a composite of negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual clinical involvement (nail totally clear) of the target nail 12 weeks after the 48-week treatment course.

The 10% nail solution of the antifungal terbinafine also met the secondary endpoints of improving responder rate and mycological cure rate at week 60 vs. vehicle...

BCIQ Company Profiles

Almirall S.A.